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Abstract
Objective: The first antiseizure medication (ASM) is ineffective or intolerable in 
50% of epilepsy cases. Selection between more than 25 available ASMs is guided by 
epilepsy factors, but also age and comorbidities. Randomized evidence for particular 
patient subgroups is seldom available. We asked whether register data could be used 
for retention rate calculations based on demographics, comorbidities, and ASM his-
tory, and quantified the potential improvement in retention rates of the first ASM 
in several large epilepsy cohorts. We also describe retention rates in patients with 
epilepsy after traumatic brain injury and dementia, patient groups with little available 
evidence.
Methods: We used medical, demographic, and drug prescription data from epilepsy 
cohorts from comprehensive Swedish registers, containing 6380 observations. By 
analyzing 381 840 prescriptions, we studied retention rates of first- and second- line 
ASMs for patients with epilepsy in multiple sclerosis (MS), brain infection, dementia, 
traumatic brain injury, or stroke. The rank of retention rates of ASMs was validated 
by comparison to published randomized control trials. We identified the optimal 
stratification for each brain disease, and quantified the potential improvement if all 
patients had received the optimal ASM.
Results: Using optimal stratification for each brain disease, the potential improve-
ment in retention rate (percentage points) was MS, 20%; brain infection, 21%; demen-
tia, 14%; trauma, 21%; and stroke, 14%. In epilepsy after trauma, levetiracetam had 
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1 |  INTRODUCTION
The first tried antiseizure medication (ASM) is ineffective 
or intolerable in 50% of cases.1 While ASM selection is in-
fluenced by the type of epilepsy and patient characteristics 
such as age and other medical conditions,2 previously tried 
ASMs also provide clues, as drugs with similar modes of ac-
tion tend to have similar efficacy and side effects.3 After a 
trial- and- error process, two thirds of patients can eventually 
achieve seizure freedom.1 There is seldom enough informa-
tion beforehand on which ASM will be most effective in the 
individual patient. Personalized medicine, a concept refer-
ring to the prediction of treatment effectiveness based on the 
characteristics of an individual patient, is not yet possible but 
greatly needed in epilepsy.4- 8
The challenges posed by the complexity of ASM selec-
tion are well recognized, and selection algorithms have been 
developed based on expert opinions.3,9,10 Real- world data on 
ASM effectiveness would be of complementary benefit, but 
collection of long- term randomized evidence is difficult, es-
pecially for particular subsets of patients. Most clinical trials 
in epilepsy have heterogeneous populations with regard to 
comorbidities and age, follow patients for a few months, and 
evaluate adjunctive therapy in patients with drug- resistant 
epilepsy.11 Real- world longitudinal data of ASM use and the 
ability to select narrow patient populations for prognostica-
tion is therefore needed. To address these challenges practi-
cally, we have previously used the Swedish drug prescription 
register to describe ASM retention rates in epilepsy after 
stroke and demonstrated concordance between our register- 
based real- life data and data from randomized controlled 
trials in the same patient group, showing the potential in 
the immediate clinical use of models derived from register 
data.12- 15 How to provide personalized therapy in epilepsy 
based on prediction of treatment effectiveness for a particular 
individual, however, remains an unsolved issue. Such predic-
tions would need data and prediction algorithms incorporat-
ing multiple factors. Whether national registers of health and 
prescription data offer enough information to be useful for 
improving ASM selection is not known.
We analyzed retention rates of ASM in several Swedish 
population- based cohorts of focal epilepsy with a simulta-
neous brain disease— a situation with many ASM options. 
By stratifying patients optimally with regard to age, sex, and 
brain disease, we quantified potential for improvement of re-
tention rates, had all patients been given the best first- line 
ASM for their stratum. We also described ASM retention 
rates in posttraumatic epilepsy and dementia, common forms 
of epilepsy where data to guide treatment are scarce.
the highest retention rate at 80% (95% confidence interval [CI] = 65– 89), exceeding 
that of the most commonly prescribed ASM, carbamazepine (p = .04). In epilepsy 
after dementia, lamotrigine (77%, 95% CI = 68– 84) and levetiracetam (74%, 95% 
CI = 68– 79) had higher retention rates than carbamazepine (p = .006 and p = .01, 
respectively).
Significance: We conclude that personalized ASM selection could improve retention 
rates and that national registers have potential as big data sources for personalized 
medicine in epilepsy.
K E Y W O R D S
big data, comorbidity, epidemiology, personalized medicine
Key Points
• ASM retention rates were calculated in cohorts 
with epilepsy after stroke, trauma, multiple scle-
rosis, dementia, and brain infections based on na-
tional register data
• The calculated retention rates were similar to re-
tention rates in randomized controlled trials
• If patients had been given the optimal ASM with 
regard to sex and age, the retention rate of the first 
ASM could potentially be 14%– 21% higher
• Previously used ASMs provide information about 
the retention rate of the next ASM
• We conclude that register- based statistics could 
provide complementary information to expert 
ASM selection algorithms in personalized medi-
cine in epilepsy
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2 |  MATERIALS AND METHODS
2.1 | Registers
The study is based on datasets originally compiled from 
comprehensive national Swedish registers: the National 
Patient Register (NPR), Drug Register (DR), Cause of Death 
Register (CDR), Swedish Stroke Register, SVEDEM (na-
tional dementia register), and SMSreg (national multiple 
sclerosis [MS] register). The NPR is a register of all con-
tacts with hospital- based out- or inpatient care in Sweden 
and was started in 2001, with complete coverage from 2005. 
Reporting to the NPR is mandatory for all health care pro-
viders in Sweden. The DR started on July 1, 2005 and con-
tains information on all pharmacy- dispensed prescriptions in 
Sweden. The CDR contains information on all dates of death 
and causes of death. All registers are linked by personal iden-
tification numbers unique to each Swedish inhabitant.
2.2 | Study population
We included participants identified in previous cohort studies 
on acquired epilepsy after different brain diseases: MS, brain 
infection, dementia, trauma, or stroke (Table 1).16 These 
datasets represent a population with probable focal onset 
seizures. The underlying brain diseases represent population- 
wide materials with regard to different etiological subgroups 
(Table 2).
In these studies, epilepsy was defined as the occurrence 
of the International Classification of Diseases, 10th Revision 
(ICD- 10) code G40 in the NPR, except for the stroke co-
hort where, to comply with the current International League 
Against Epilepsy (ILAE) definition of epilepsy, all seizure- 
related diagnostic codes (G40, R568, G41) occurring more 
than 7 days after the initial stroke were considered evidence 
of epilepsy.
We included individuals from the above datasets with the 
first diagnosis of epilepsy after the start of the DR on July 1, 
2005, which allowed us to track the entire ASM history. The 
specific inclusion criteria were a diagnosis of epilepsy as de-
fined in the original cohort studies, the first diagnosis of ep-
ilepsy after July 1, 2005, and the first prescription of a valid 
ASM after the first seizure. The combination of an ICD- 10 
code for epilepsy and the prescription of an ASM is highly 
specific for epilepsy in administrative data.21 Patients were 
excluded if they died within 60 days of their brain disease 
diagnosis to minimize impact of acute symptomatic seizures 
and avoid artificially increased retention rates on commonly 
selected first treatments. Patients with two or more ASMs 
dispensed within 7  days of initial treatment start were ex-
cluded to avoid effects of initial polytherapy on the retention 
rate for a single treatment. The inclusion and exclusion steps 
are illustrated in Figure 1A.
The datasets were anonymized by the National Board of 
Health and Welfare, and therefore we cannot exclude that 
some patients could exist in several cohorts because of mul-
tiple brain diseases prior to epilepsy. The inclusion and ex-
clusion criteria resulted in a dataset of 6380 observations in 
total.
2.3 | ASM tracking
All prescriptions of ASMs (defined as Anatomical 
Therapeutic Chemical code N03) for the included individu-
als were identified, resulting in a dataset of 381 840 dispen-
sations. We defined ASM start as the first dispensation date. 
Patients were followed until death or the end of the DR data. 
The retention rate was calculated by Kaplan– Meier (KM) 
analysis, and confidence intervals (CIs) were calculated 
using Greenwood's exponential formula. Swedish prescrip-
tions are valid for 1 year, and each dispensation is usually 
sufficient for 3 months of use.22 Discontinuation was defined 
as more than 12 months without a new prescription and set at 
3 months after the last dispensation. The same algorithm has 
been used previously to describe first- line ASM use in the 
MS23 and stroke datasets.24 Dispensations of gabapentin, pre-
gabalin, and clonazepam are frequently used for other indi-
cations than epilepsy and were therefore considered invalid.





year n Female, % AEDs, n, median (max)
Age at epilepsy onset, 
years, median (range)
MS 2005 2015 149 66 1.70 (6) 50.5 (18– 81)
Infection 2005 2018 243 55 1.71 (9) 59 (19– 93)
Dementia 2007 2018 699 55 1.23 (4) 81 (47– 98)
Trauma 2005 2018 265 35 1.49 (6) 61 (18– 94)
Stroke 2005 2015 5024 45 1.33 (7) 76 (18– 100)
Total 2005 2018 6380 46 1.35 (9) 75 (18– 100)
Note: The number of patients with epilepsy for each preexisting brain disease in the dataset is shown.
Abbreviations: AED, antiepileptic drug; MS, multiple sclerosis.
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The analyses are visualized in the supplemental material. 
Individual study cohorts can be selected based on brain dis-
ease, and delimited with regard to sex and age at epilepsy 
onset. If two ASMs were dispensed within 7 days, the med-
ication was considered polytherapy, and the patient was not 
included in the analysis of either of the ASMs. Retention 
rates were only estimated if at least 10 individuals using the 
same ASM were available. Second- line ASM was defined as 
strictly the second ASM used by the patient. The second- line 
ASM could be used simultaneously as the first- line ASM as 
long as the usage started at least 7 days after the first ASM. 
Probability values comparing retention rate curves with one 
ASM in each curve were calculated using a log( − log( ⋅ )) 
test25; the procedure for obtaining probability values for the 
optimal retention rate is described in the next section.
2.4 | Calculation of optimal retention rate
To calculate the potential for improvement we explored the 
optimal stratification for each brain disease regarding sex or 
no sex split, and different splits by age. The age splits were 
(no age split), (60), (70), (80), (50, 80), (40, 60, 80), (60, 70, 
80, 90), (40, 50, 60, 70, 80, 90). The optimal stratification 
was found by Kaplan- Meier (KM) curves of the ASMs with 
the highest 5- year retention rate for each assessed stratum, 
and events in this curve were integrated into a new KM 
curve, which was compared to all other ASMs combined. 
The stratification set with the largest difference in the 5- year 
retention rate was considered optimal. If the retention rate of 
an ASM was not available at 5 years, the latest available re-
tention rate was used as an estimation. To test if the differ-
ence between the highest retention rate ASMs and the other 
ASMs was significant, we adapted an unbiased cluster 
test26 since using a regular test could inflate the Type I error. 
Each stratum's retention rate was considered as a data point, 
and the highest retention rate ASMs and the other ASMs 
were each considered as a cluster (̂1 and ̂2, respectively). 
The p- value is defined as p = ℙ
(
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features in the data. Here, retention rate is the one feature of 
the data, meaning q = 1. σ is the standard deviation of the 
data points. We used the mean weighted by the number of 









. X is the set of all data points,  is the greenwood 
MS 60.4% relapsing– remitting MS
29.3% secondary progressive MS
8.9% primary progressive MS
1.4% progressive relapsing MS
Brain infection 47.7% other meningitis
7.8% abscess
7.3% tick- borne encephalitis
3.7% herpes simplex virus encephalitis
10.3% other encephalitis
Dementia 28.4% Alzheimer disease, onset at >65 years
3.4% Alzheimer disease, onset at <65 years
22% unspecified dementia
19% mixed Alzheimer disease and vascular
19% vascular
2.2% dementia with Lewy bodies
1.6% frontotemporal dementia
1.5% Parkinson disease
2.8% other type of dementia
Trauma 68.2% mild injury
14.7% extracerebral injury
7.8% diffuse cerebral injury
5.4% fracture
3.8% focal cerebral injury
Stroke 87.3% ischemic stroke
9.6% intracerebral hemorrhage
3.1% unspecified stroke
Note: Subjects are from the following cohort studies: MS,17 brain infection,18 dementia,19 trauma,20 and 
stroke.16
Abbreviation: MS, multiple sclerosis.
T A B L E  2  Etiologies of brain diseases
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variance, and p is the number of patients. x� () is x perturbed 




 is the set of all valid  where 
the clusters do not switch data points. In this case, the upper 
bound is infinite and the lower bound of the perturbation is 
the difference between the mean of the clusters and the 
minimum difference in retention rate between a highest 
retention rate ASM and its corresponding other ASMs for 
the same stratum, 
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− min (D) ,∞
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. D 
is the set of differences in retention rate between a highest 
retention rate ASM and its corresponding other ASMs. The 
F I G U R E  1  (A) Flow chart of data processing. (B) Proportions of datasets. (C) Distribution of epilepsy onset age. (D) Validation of the time 
intervals in the algorithm; sensitivity analysis of the 5- year retention rate (y- axis) of antiseizure medications (ASMs) when the grace period (x- axis) 
is changed. The greatest effect on retention rates was seen with increasing the grace period to 1 year, which is a point from where the rank of ASMs 
becomes stable while the retention rate is kept from being artificially high. (E) Comparison to the randomized trial SANAD showed similar 5- year 
retention rates: lamotrigine, 68% (95% confidence interval [CI] = 64– 71); topiramate, 57% (95% CI = 22– 82); carbamazepine, 57% (95% CI = 54– 
59). Carbamazepine was the most common (n = 3020, 47%) followed by lamotrigine (n = 775, 12%) and lastly topiramate (n = 10, <1%). SANAD 
study hazard ratios compared to carbamazepine: lamotrigine, .78 (95% CI = .63, .97); topiramate, 1.22 (95% CI = .99, 1.49).27 Hazard ratio greater 
than 1 indicates that the retention rate is lower. AED, antiepileptic drug; MS, multiple sclerosis
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idea is that if  is smaller than a specific value, the clusters 
will have been pushed together so close that at least one pair 
of strata has passed each other, and the clusters will no longer 
consist of the same data points. 100000 samples of  were 
drawn to estimate each p- value.
2.5 | Ethical permission
The study was approved by the Swedish Ethical Review Authority 
(approval number 2020– 01829). All handling of personal data 
was done in agreement with Swedish data protection laws.
3 |  RESULTS
3.1 | Validation of registry- derived ASM 
retention rates
Our method was based on a prescription renewal grace pe-
riod of 12 months and ASM discontinuation set to 3 months 
after the last dispensation. We verified the validity of these 
assumptions by assessing retention rates of ASMs for vary-
ing time intervals of renewal, showing large shifts in reten-
tion rate rank for shorter time intervals than 12 months and 
little effect beyond 12 months (Figure 1D), suggesting that 
12 months is a reasonable grace period.
Next, KM estimates of the retention rates of ASMs were 
compared to the randomized clinical trial SANAD, the largest 
randomized controlled trial in focal epilepsy, the kind of epi-
lepsy in our datasets, to date.27 Our first- line ASM retention 
rates for the full population were similar to those of SANAD; 
lamotrigine had the highest retention rate and carbamazepine 
had a significantly lower retention rate both after 1 year and 
after 5 years (p < .001; Figure 1E). Topiramate had a lower re-
tention rate than carbamazepine in SANAD, but the number of 
patients taking topiramate in our material was too low for com-
parison. We also conducted sensitivity analyses with a popula-
tion matched more closely to that of SANAD with only stroke, 
trauma, and infection within ages 20– 60 years (Figure S1), 
and all brain diseases except stroke (Figure S2), which yielded 
similar retention rates for lamotrigine and carbamazepine.
The analyses have been condensed into web- based soft-
ware, which allows visualization of the dataset regarding 
first- line ASM and the second- line ASM for individuals who 
tried a particular first- line ASM (Appendix S1).
3.2 | Optimal stratification and ASM 
selection for maximal retention rate increase
We quantified the potential for improvement of first ASM 
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highest retention rate for their subgroup as initial monother-
apy, by determining the optimal stratification of sex and age 
for each brain disease with regard to retention rate improve-
ment (Table 3). There was a potential increase in the 5- year 
retention rate in each of the diseases (increase in percent-
age points): MS, 20%; brain infection, 21%; dementia, 14%; 
trauma, 21%; stroke, 14% (Figure 2A). The potential increase 
for the group of patients using a suboptimal treatment— the 
difference in retention rate between the highest retention rate 
ASM and all other ASMs combined— was for each disease: 
MS, 27% (p = .05); brain infection, 25% (p = .04); dementia, 
18% (p = .10); trauma, 25% (p = .07); stroke, 16% (p < .001). 
An example of stratification is patients with trauma, where 
optimal stratification was based on sex. Males had a higher 
retention rate with levetiracetam (75%, 95% CI = 54– 87) 
than with all other ASMs (43%, 95% CI = 34– 53). Females 
had a higher retention rate with lamotrigine 70% (95% CI = 
33– 89) than with all other ASMs (48%, 95% CI = 34– 60).
3.3 | Posttraumatic epilepsy and epilepsy 
in dementia
We studied ASM treatment of epilepsy after traumatic brain 
injury and epilepsy in dementia, common forms of acquired 
epilepsy, for which there is currently inadequate evidence to 
guide treatment. In trauma, levetiracetam had a significantly 
higher retention rate than the most common ASM, carbamaz-
epine (p = .04); carbamazepine was the most common first- 
line ASM (n = 125, 47%), followed by levetiracetam (n = 50, 
19%), valproic acid (n = 40, 15%), and lamotrigine (n = 35, 
13%). The 1- year retention rate was 80% (95% CI = 65– 89) 
for levetiracetam, 77% (95% CI = 60– 88) for lamotrigine, 
65% (95% CI = 48– 78) for valproic acid, and 62% (95% CI 
= 52– 70) for carbamazepine. No differences other than that 
between levetiracetam and carbamazepine were statistically 
significant.
For epilepsy in dementia, levetiracetam and lamotrigine 
were significantly better than carbamazepine, with p = .006 
and p = .01, respectively. The most common first- line ASM 
was levetiracetam (n = 290, 41%), followed by carbamaze-
pine (n = 182, 26%), lamotrigine (n = 108, 15%), valproic 
acid (n  =  95, 14%), and oxcarbazepine (n  =  12, 2%). The 
1- year retention rates were 77% (95% CI = 68– 84) for lamo-
trigine, 74% (95% CI = 68– 79) for levetiracetam, 67% (95% 
CI = 56– 76) for valproic acid, 61% (95% CI = 53– 68) for 
carbamazepine, and 50% (95% CI = 21– 74) for oxcarbaze-
pine (Figure 3B).
3.4 | Previously failed ASM provides 
information about the efficacy of the next ASM
Finally, we asked whether the first failed ASM influenced 
retention rates of the second ASM. This analysis was only 
possible in the larger brain disease cohorts, and for the more 
common drugs. We show an example where the rank of two 
ASMs is changed based on this conditioning. For initial ther-
apy in poststroke epilepsy, lamotrigine had a higher 1- year 
retention rate, 84% (95% CI = 80– 87), than levetiracetam, 
78% (95% CI = 75– 82), p = .03, but in patients with stroke 
who used valproic acid as their first ASM, levetiracetam had 
a higher retention rate, 93% (95% CI = 86– 97), than lamo-
trigine, 73% (95% CI = 61– 82), p = .002.
F I G U R E  2  (A) The estimated increase in 5- year retention rate by using the antiseizure medication (ASM) with the highest retention rate for 
every patient stratification. (B) Retention rates of ASMs for males with trauma. Levetiracetam, which had the highest retention rate, is compared to 
the Kaplan– Meier curve of the events of all other ASMs. MS, multiple sclerosis
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4 |  DISCUSSION
In this nationwide study on data from comprehensive health 
registers, we found a potential improvement in retention rate 
of the first ASM of 14%– 21% in patients with epilepsy in a 
range of brain diseases. This indicates that the application of 
personalized medicine— basing treatment decisions on statis-
tics derived from representative patient groups— has signifi-
cant potential in epilepsy care, and that better use of available 
ASMs could significantly improve outcome. We also found 
different retention rates of ASMs for patients with different 
brain diseases, which supports the clinical relevance of the 
2017 ILAE classification of epilepsies, introducing etiology 
as a separate classification axis.28 We also demonstrate that 
data from national registers offer a feasible and powerful way 
of determining retention rates for different ASMs based on 
individual patient characteristics. Although observational 
data can never replace randomized evidence, it is unlikely 
that evidence on retention rates for specific patient groups 
will emerge from randomized controlled trials, which often 
struggle to recruit a sufficient number of patients to demon-
strate overall efficacy.
We also found that ASM history is of importance when 
selecting a new treatment. Although it is often emphasized 
in clinical practice, there are few data to support this notion. 
Our data indicate that simply ranking ASMs based on pa-
tient characteristics and trying ASMs in that order does not 
take full advantage of the available data. Instead, previously 
failed treatments are meaningful because they reveal infor-
mation about potentially unmeasured variables,29 perhaps 
side effects specific to mechanism of action. This is illus-
trated in our example of lamotrigine having a higher 1- year 
retention rate than levetiracetam in the stroke population, but 
for patients who tried valproic acid, the order was reversed. 
Methodologically, our study demonstrates that national reg-
isters provide enough data to allow high- resolution stratifica-
tion and the possibility to compare second- line ASMs.
There are several limitations to our study. The DR was 
started as late as 2005, which allows only a few years of ASM 
tracking, and the algorithm for ASM retention was relatively 
crude. However, we validated our results against data from 
clinical randomized trials. The determination of optimal 
ASM use is valid if the age distribution within each stratifi-
cation is similar or if a shift in age distribution is irrelevant 
for the retention rate in that stratification, and if physicians 
prescribe ASM based on, at most, brain disease, sex, and age. 
Patient register data do not reveal whether a preceding brain 
disease actually caused the epilepsy, or why particular medi-
cations have higher retention rates in some patient subgroups. 
Nor do the data contain information about adjudicated sei-
zures for a patient after a dispensed ASM or the existence of 
psychogenic nonepileptic seizures. Effect on seizures, clini-
cal decisions, and side effects could all matter. For instance, 
in patients with previous stroke and complicated secondary 
vascular prophylaxis, ASMs with several drug– drug inter-
actions may need to be replaced. In Alzheimer disease and 
other types of dementia, a cholinergic deficit could enhance 
cognitive symptoms, potentially causing anticholinergic 
medications such as carbamazepine and oxcarbazepine to be-
come intolerable.30
The underlying datasets represent a broad range of poten-
tial causes of acquired epilepsy. Survival times between the 
underlying brain diseases vary substantially, which supports 
comparing patients only within their own etiological category 
for calculations of potential improvement in retention rates. 
It is important to note that the retention rates in our study 
F I G U R E  3  (A) Posttraumatic epilepsy. (B) Epilepsy after dementia. Number at risk is given below each graph
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reflect the situation for adult onset focal epilepsy, and not 
other epilepsy syndromes. Furthermore, retention rate, which 
is an integrated measurement of efficacy and tolerability of 
an ASM, rests on the assumption that patients quit their treat-
ment if and only if the treatment is ineffective or intolerable. 
There might be cases where seizure- free patients pause their 
medication to evaluate whether they can remain seizure- free 
without it and simultaneously avoid the side effects of the 
ASM. However, if the magnitude of treatment pausing is sim-
ilar for all treatments, this should not affect the rank of ASMs. 
There might also be a discrepancy between the dispensation 
of the drugs and the drugs used by the patient, but we assume 
that this difference is small, as patients should not, in gen-
eral, pick up new drugs if they are not planning to continue 
to use them. The retention rate is built on the assumption 
that clinicians prescribe treatments for 3 months at a time, 
and that there are at most 12 months between dispensations. 
The sensitivity analysis in Figure 1D shows that the retention 
rate for different ASMs has approximately the same ranking 
when the 12 months assumption is changed. Finally, there is 
a time lag for register- based studies. Several new ASMs such 
as perampanel, brivaracetam, and lacosamide have become 
more popular in recent years. National registers are updated 
continuously, which offers an opportunity to incorporate in-
formation on new ASMs continuously, but to elucidate their 
retention rates, future studies are needed. Because the origi-
nal cohorts are population- wide, there could be some overlap 
between cohorts; for instance, patients with stroke may later 
have brain injury (trauma) and then develop epilepsy. For 
some of the brain diseases, particularly epilepsy in MS, we 
could retrieve data for only a small number of patients. This 
can be partly explained by our requirement of epilepsy onset 
after the start of the DR in 2005. Ideally, data from several 
countries with comprehensive registers should be combined 
in future analyses.
There are also strengths to our study. The comprehensive 
Swedish national registers allowed inclusion on a nationwide 
scale, which enhances the external validity of our findings. 
The combination of a diagnostic code for epilepsy and a pre-
scription for an ASM has been shown to be highly specific 
for epilepsy,21 and an epilepsy diagnosis in the NPR has a 
positive predictive value of 90% for the disease.31 The DR 
is comprehensive and contains all prescriptions of dispensed 
drugs in Sweden, making it robust to factors influencing 
many clinical studies, such as patient relocation. The result-
ing retention rates are in agreement with those described in 
randomized studies on focal epilepsy such as the SANAD 
study of a heterogeneous population and two previous ran-
domized clinical trials (RCTs) of poststroke epilepsy.14,15,27 
Our estimates of potential improvement of retention rates are 
similar to those reported in a study using machine learning 
on prescription data.32 Depending on the underlying etiology, 
14%– 21% of patients with new onset focal epilepsy in our 
dataset did not receive the ASM with the highest likelihood 
of success for their age and sex.
Real- world data from registers could be of great comple-
mentary use for clinicians, in addition to RCT data and expert- 
based algorithms.3,9,10 An exciting prospect is the potential 
of using register data for machine learning. Conceptually, 
machine learning has been demonstrated to be able to use 
clinical and prescription data to identify ASM treatments 
with the lowest likelihood of treatment change.32 The obser-
vational nature of register data comes with challenges, but 
nonrandomized observations and confounding could be han-
dled by statistical matching techniques and bounding of the 
confounding.29,33,34,35 The problem of right- censored data in 
cohorts with high mortality was handled with the KM esti-
mator in this study, but other methods would be needed for 
machine learning.36- 38 In summary, register- based analysis of 
ASM retention rates could be useful for personalized medi-
cine in epilepsy.
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